Navigation Links
LMU Munich researchers highly endowed with EU funding

Two junior researchers from Ludwig-Maximilians-Universitt (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David Vhringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

Professor Jens Michaelis will be studying how DNA is structurally rearranged in the cell nucleus in his project "ATP-dependent nucleosome remodeling Single molecule studies and super-resolution microscopy". In higher cells, the threadlike DNA molecule wraps around so-called histone proteins, together forming larger units called nucleosomes. Packed tightly like this, the DNA is protected, but sections of it have to be kept constantly accessible. Only so can the genetic information be read and the DNA duplicated for cell division, for example. This restructuring of nucleosomes is therefore an essential cellular process and, despite extensive experimental effort, its mechanistic detail is still not perfectly understood. This is where the 1.4 million euro sponsored project comes in: Michaelis intends to visualize this dynamic and energy-consuming nucleosome restructuring at the molecular level. Highly complex microscopic techniques, some of which originated in the physicist's own lab, will at last help demonstrate this tiny-scale process in a mechanistic model.

Jens Michaelis was born in 1971 in Mainz. After studying physics at Ulm University, he moved to the University of Oregon, USA. Jens Michaelis earned his doctorate in 2000 at Universitt Konstanz with his thesis on "Microscopy with a single-molecule light source". Following this, he worked as a postdoc for three years at the University of Berkeley, USA. In 2003, he came to the Institute of Physical Chemistry of LMU Munich as the head of a research group. For his successful work, he was appointed junior professor in 2006. He has been a professor in the Department of Chemistry and Biochemistry, and has been working in the cluster of excellence Center for Integrated Protein Science Munich (CIPSM) since 2008.

The project "Persistence of allergic sensitization" of Privatdozent David Vhringer shall be funded with the maximum grant of more than 1.7 million Euros. The immunologist intends to study immune factors essential to the onset of allergy. This misguided response by the body's defenses already concerns up to a quarter of the population in the western industrial nations, according to estimates, and the trend is upward. An allergic reaction is triggered by the activation of mast cells and basophilic granulocytes. Both types of immune cell are activated by so-called IgE antibodies, which recognize harmless substances the respective allergens and thus trigger the undesired immune response. The IgE immunoglobulins can bind onto mast cells and basophilic granulocytes and remain in the body for many years, thereby causing the allergy to persist. From a therapeutic perspective, it would be desirable to eliminate IgE-producing B cells selectively. In the scope of his EU-funded project, Vhringer shall be addressing various problems concerning the formation and lifespan of IgE-producing B cells.

David Vhringer was born in 1970 in Stuttgart. He studied biology at the Universities of Tbingen and Freiburg. In Freiburg, he earned his doctorate with his thesis on "T cell mediated autoimmune hepatitis and characterization of the Killer cell Lectin-like Receptor G1". Following that, he worked from 2002 to 2005 as a postdoc at the University of California San Francisco, USA. In 2005, he came to the Institute of Immunology of LMU Munich as the head of an Emmy Noether junior research group. He completed his habilitation in 2008.


Contact: Dr. Jens Michaelis
Ludwig-Maximilians-Universitt Mnchen

Related biology news :

1. Environmentally green beer: Munich brewing engineers research energy savings
2. Munich researchers discover new target for tailored antibiotics
3. 2 Alexander von Humboldt professorships go to LMU Munich
4. Munich researchers discover key allergy gene
5. Fighting sleep, Penn researchers reverse the cognitive impairment caused by sleep deprivation
6. UBC researchers find key microbial indicator of ocean health
7. Clemson researchers say algae key to mass extinctionss
8. Texas A&M researchers find new mechanism for circadian rhythm
9. Researchers find ways to encourage spinal cord regeneration after injury
10. CCNY researchers study scientific collaboration in age of internet
11. Carnegie Mellon researchers save electricity with low-power processors and flash memory
Post Your Comments:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
Breaking Biology Technology: